Introduction
CD45 is a structurally heterogeneous, transmembrane protein-tyrosine phosphatase found exclusively on nucleated cells of hematopoietic origin. The heterogeneity results from differential RNA splicing of six exons in the extracellular domain [1] [2] [3] . The isoforms are expressed in a cell type-specific pattern. B cells predominantly express the isoform containing all exons 4, 5 . Thymocytes express the lowest molecular weight isoforms resulting from the removal of three and four exons [2] [3] [4] . T cells have a varied isoform expression pattern that is dependent upon the differentiation state, function and prior antigenic exposure 3 . In addition to the structural heterogeneity of CD45 proteins, CD45 allelic differences also have been noted. At least three CD45 alleles in inbred mice strains have been identified based on antigenic differences and polymorphic sequence variations 2, 6, 7 . The Ly5 a (CD45. 1) and Ly5 c alleles are found in only a few strains while the Ly5 b (CD45.2) allele is expressed by most of the established lines. The sequence differences between the three alleles produce proteins which differ in their reactivity to specific monoclonal antibodies 7 CD45 has been shown to be essential for T cell development [8] [9] [10] and for the function of both T and B lymphocytes [8] [9] [10] [11] [12] [13] [14] [15] . In CD45-null mice, thymocyte development is blocked resulting in few peripheral T cells. The function of these T cells in the periphery also is defective and they do not proliferate in the presence of activators or mitogens. B cell maturation in the CD45-negative mice is not effected by the CD45 deficiency although their proliferative response to anti-IgM is abrogated 9, 10 . With regard to lymphocyte function, CD45 is essential for signaling through the T as well as B cell antigen receptors [11] [12] [13] [14] 16, 17 , and is required for positive and negative regulation of the Src family kinases associated with these receptors [18] [19] [20] [21] . Human severe combined immunodeficiencies (SCID) are a group of genetic diseases in which T cell development is blocked and other lymphoid lineages are variably affected 22, 23 . The genetic defects of many forms of the disease have now been identified including mutations in the common -chain of cytokine receptors found in X-linked SCID and alterations in several other genes, such as JAK-3 kinase, Rag-1, and Rag-2, which cause autosomal recessive SCID 23, 24 . Autosomal recessive SCID also results from a deficiency in the CD45 gene [24] [25] [26] . The phenotype of these patients is similar to that of CD45-knockout mice 9, 10 ; not only are peripheral T cell numbers decreased but T cells that are present fail to respond to mitogens 26 . Although B cell numbers are normal, these cells also are dysfunctional 25, 26 . We have generated a CD45 minigene encoding the CD45.1 allele in which two cDNA regions spanning exons 1b -3 and 9 -33, flank genomic DNA containing the alternatively spliced exons 4 -8. Transcriptional regulation of the minigene from the native CD45 promoter region was ineffective but the human LFA-1 promoter, which has similar tissuespecific expression characteristics to CD45, produced high levels of CD45 expression in lymphoid cell lines 27 . The demonstration that correctly spliced, cell lineage-specific CD45 mRNAs were produced in both T and B cell lines indicates the minigene construct has many of the expression properties of the endogenous CD45 gene. These expression characteristics in vitro were encouraging; however, the question remains whether the minigene can supply functional CD45 isoforms to the various leukocyte lineages. To determine whether the minigene, LFAiT200, could restore the functional and developmental properties of the 4 immune system, we generated transgenic CD45-null mice carrying the minigene. The introduction of the CD45 minigene is sufficient to overcome the SCID-associated defects and with an appropriate delivery system represents a potential gene therapy for human CD45-deficient SCID.
Materials and Methods
Mice. Seven to 16 week old C57BL/6 (Harlan, San Diego, California, USA), SJL/J and CD45-deficient C57BL/6 4 mice (Jackson Labs, Bar Harbor, Maine, USA) were used. Transgenic mice were generated by injecting the 20 kb SfiI-NotI fragment of pLFAiT200 containing the CD45 minigene 27 into fertilized (BALB/c x C57BL/6)F2 mouse oocytes. Mice carrying the transgene were identified using DNA isolated from tail snips using the DNeasy Tissue Kit (Qiagen, Valencia, Caifornia, USA) by PCR analysis. The antisense primer includes bases 1 to 17 of exon 3 with additional nucleotides containing an XhoI cloning site at the 5' end (5'-CTTTTGACTCGAGGGTGTAGGTGTTTGCC-3'). The sense primer consists of bases 32 to 50 of exon 1b with additional nucleotides including a ClaI cloning site added at the 5' end (5'-GTGCGGATCGATAAGTGGTTTGTTCTTAGGG-3'). The first cycle was 94 0 C, 4 min; 60 0 C, 1 min; 72 0 C, 1 min. Cycles 2-34 were 1min at 94 0 C, 1 min at 60 0 C, and 1 min at 72 0 C. A 211 bp fragment results from the presence of transgene DNA whereas no signal is observed from the endogenous CD45 gene due to the approximately 50 kb of sequence between the primer sites. Southern analysis was used to confirm the PCR results. Total genomic DNA was digested with the restriction enzyme, BamHI. The probe utilized a BamHI cDNA fragment extending from exon 13 to exon 22. These CD45 transgenic mice were crossed with the CD45-null strain until CD45 transgene positive progeny were obtained on a CD45-null background.
Quantitation of Transgene Copy
Number. The number of integrated copies of the transgene was determined by Southern analysis. Total genomic DNA was digested with a combination of restriction enzymes EcoRI and BamHI. The hybridization probe consisting of intron sequence between exons 8 and 9 detected a 2.3 kb fragment specific for the transgene and a 2.0 kb band diagnostic of the endogenous gene. The approximate copy number was estimated by comparing the hybridization intensity of the transgenic fragment to that of the endogenous band.
Proliferation Assays. T cell proliferation assays were conducted in 96 well microtiter plates using 1 x 10 6 cells per well for spleen cells isolated from CD45-null mice and 2 x 10 5 spleen cells per well for all other strains. T cell activators were concanavalin A (ConA) (Sigma, St Louis, Missouri, USA) at 1 µg/ml or a combination of anti-CD3 and anti-CD28 (PharMingen, La Jolla, California, USA) at 2 µg/ml each. For the mixed lymphocyte reaction (MLR) assay, 4 x 10 5 responder cells were added to 2 x 10 5 , 4 x 10 5 , and 8 x 10 5 irradiated (2000 rad) spleen stimulator cells from MHC-allogeneic SJL mice or irradiated responder cells. In the anti-IgM proliferation assay, 20 µg/ml of the F(ab') 2 
Reverse Transcription and Polymerase Chain Reaction (RT-PCR).
Total RNA was isolated from spleen and thymus using TRIZOL (Life Technologies, Gaithersburg, Maryland, USA) following manufacturer's directions. Spleen cells were untreated, exposed for 3 days to ConA or LPS. RT-PCR was performed using the GeneAmp RNA PCR kit (Applied Biosystems, Foster City, California, USA) according to manufacturer's directions. The antisense oligonucleotide used for both cDNA synthesis and PCR amplification, 5'-GGAGCACATGAGTCATTAGACACACTGATG-3', consists of bases 155-184 of CD45 exon 9. The sense primer includes bases 21-51 of exon 2 and has the sequence, 5'-GCACAGCTGATCTCCAGATATGACCATGGGT-3'. cDNA was synthesized for 15 minutes at 42 0 C followed by inactivation of reverse transcriptase for 5 min at 95 0 C. The first PCR cycle was 3 min at 94 0 C, 1 min at 70 0 C, and 2 min at 72 0 C. Cycles 2-24 were 1 min at 94 0 C, 1 min at 70 0 C, and 2 min at 72 0 C. The amplified products were separated on an alkaline agarose gel and identified as described previously 28 .
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Immunization and ELISA. Five mice of each type, transgenic F, C57BL/6 and CD45-null, were immunized by intraperitoneal injection of 0.1 mg DNP-KLH (Calbiochem, San Diego, California, USA) in 0.1 ml CFA (Sigma). Mice were bled 7, 14 and 21 days after immunization and serum prepared.
The ELISA was performed as described 29 . Briefly, wells were coated overnight with 0.05 mg DNP-BSA in 0.1 M carbonate buffer, pH 9.6, washed with PBS, blocked with 1% BSA/PBS, washed with PBS and incubated with serial dilutions of mouse serum for 4 hours at room temperature. Rabbit anti-mouse IgM or IgG at a dilution of 1/1000 was added for 2 hours at room temperature, washed with PBS and incubated overnight at 
Results
Generation of Transgenic Mice. The 20 kb CD45 expression fragment of pLFAiT200 ( Fig.  1 ) was injected into fertilized mouse oocytes for the production of transgenic mice. Three founder mice were initially identified by PCR amplification of minigene-specific sequence from genomic DNA isolated from tail and subsequently confirmed by Southern analysis. The three founders have similar properties and here, we report our findings with transgenic mice from founder F. The number of integrated copies of the transgene in transgenic F was determined to be approximately 15 with all copies transmitted to offspring as a single inheritable unit indicating integration of all copies at one site. The transgene locus was placed on a CD45-negative background through matings with the exon 9-disrupted CD45-null mouse (CD45.2 -/-) 9 . Unless specifically stated otherwise, reference to the transgenic mouse indicates the transgene is on the CD45.2 -/-background.
7 Figure 1 . Structure of the murine chromosomal CD45 gene 30 and the minigene, pLFAiT200. (a) The map of the 115 kb murine CD45 gene shows the exon and intron organization. The 12 kb of genomic sequence contained in the minigene is indicated. (b) The structure of the CD45 minigene, pLFAiT200, is illustrated. LFA is the human LFA-1 (CD11a) promoter and UTR is the 3' CD45 untranslated region. The CD45 5' cDNA region containing exons 1b through 3 and the 3' cDNA sequence region with exons 9 through 33 are designated 1b-3 and 9-33, respectively. The hatched box indicates the genomic sequence contiguous with the UTR 3' of the CD45 poly(A) site. UTR   115 kb  10  20  30  40  50  60  70  80  90  100  110  0   8  23  33  1a 2  1b  3  13  18  28   Chromosomal CD45   a   115 kb  10  20  30  40  50  60  70  80  90  100  110  0   8  23  33  1a 2  1b  3  13  18  28   Chromosomal CD45   a   10  20  30  40  50  60  70  80  90  100  110  0   8  23  33  1a 2  1b  3  13  18  28   Chromosomal CD45   10  20  30  40  50  60  70  80  90  100  110  0   8  23  33  1a 2  1b  3  13  18  28   10  20  30  40  50  60  70  80  90  100  110  0   8  23  33  1a 2  1b  3  13  18 Since the human LFA-1 promoter drives CD45.1 transcription in the transgene, the expression characteristics of CD45.1 were compared with those of endogenous LFA-1 and CD45.2. Spleen cells were labeled with anti-CD45.1, anti-CD45.2, or anti-CD11a (LFA-1). In C57BL/6 mice, the CD45.2 positive cells are also LFA-1 positive with variable levels of LFA-1 expression (Fig. 4a) (Fig. 4a) . However, the more brightly labeled LFA + cells of the T cell lineages are more heterogeneous with respect to CD45 expression and generally express less CD45 than their wild type counterparts (Fig. 3, Fig. 4a ). Importantly, in transgenic mice hemizygous for CD45.2, all cells positive for CD45.1 are also positive for CD45.2 and vice versa (Fig. 4b) . The CD45 isoform expression pattern from the transgene was evaluated in spleen cells from C57BL/6 and transgenic mice using monoclonal antibodies specific for exon 4 (CD45RA), exon 5 (CD45RB) or exon 6 (CD45RC) and flow cytometry. The percentage of positive cells with each of these antibodies is very similar for the transgenic mice and mice expressing the endogenous CD45 gene (CD45RA, 56% ± 6%; CD45RB, 80% ± 5%; CD45RC, 60% ± 4%).
CD45.1 Expression.

SJL/J Counts Counts
The similarity of isoform expression characteristics of transgenic and normal mice was confirmed through RT/PCR analysis. Lymphocytes from the spleen and thymus of C57BL/6, CD45-null and transgenic mice were isolated. Total RNA was purified from untreated spleen and thymus cells and from spleen cells treated with Con A or LPS for 3 days. The CD45 isoforms were identified by RT/PCR using primers which flank the region of alternatively spliced exons allowing all isoforms to be detected (Fig. 5) . No CD45 mRNA was detected in cells from the CD45-knockout mouse with the conditions used. Multiple isoforms were observed in C57BL/6 spleen cells as expected of a mixture of leukocyte populations. The same expression pattern is found in the spleen cells of the transgenic mouse. ConA-induced T cell blasts show a reduction of the high molecular weight isoforms and an increase in the low molecular weight forms in both the C57BL/6 and transgenic mice. Enrichment of the B cell population by activation of B cell proliferation with LPS results in an increase in the proportion of high molecular weight isoforms. Primarily, the 789 and 89 isoforms are expressed in the thymus of C57BL/6 and transgenic mice. (Fig. 6 ).
The CD4 + cells expressing the CD44 hi , CD62L
lo memory phenotype were primarily CD45RB lo for both the wild type and transgenic mice, 73% in C57BL/6 and 64% in transgenic mice (Fig. 6 ). Thymocyte Development and T Cell Function. The CD45-null mutation causes a block in T cell development at the CD4 + CD8 + stage resulting in reduced numbers of mature, single positive thymocytes [8] [9] [10] . The presence of the CD45.1 transgene restores CD4 + and CD8 + single positive thymic T cells in the transgenic mice (Fig. 7 , Table 1 ). The restoration of thymocyte development results in increased numbers of mature T cells in the spleens of these mice (Fig. 7, Table 1 ). 
Thymus Spleen
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The values are the total number of CD4 and CD8 single positive cells in the thymus and spleen of the mouse. Averages with standard deviations were derived from the separate analyses of three thymuses and five spleens.
The functional capabilities of the peripheral T cells were determined by proliferation assays of spleen cells activated with Con A, a mixture of anti-CD3 and anti-CD28, or MHCallogeneic stimulator cells. As expected, proliferative responses to both ConA and anti-CD3/CD28 are completely abrogated in the CD45-null mice (Fig. 8a) . Expression of the CD45.1 transgene restores these proliferative responses to normal levels. Furthermore, in contrast to CD45-null cells, transgenic spleen cells are capable of normal levels of proliferation in reaction to allogeneic stimulator cells (Fig 8a) . 9 . Although the B cells of these mice respond to mitogenic stimulation by LPS, they do not proliferate in the presence of anti-IgM and do not produce an antibody response to antigen 9 . Spleen cells isolated from transgenic, CD45-null and C57BL/6 mice were activated with anti-IgM or LPS. The expression of the CD45.1 transgene in the knockout mice restores a substantial proliferative response to anti-IgM (Fig. 8b) . Responses to LPS are normal (Fig.8b) .
The ability of the CD45.1 transgenic mice to mount a primary immune response was examined. C57BL/6, transgenic and CD45-null mice were immunized with DNP-KLH. Mice were bled 7, 14 and 21 days post-immunization, and sera from each mouse were analyzed separately by ELISA for the presence of anti-DNP IgM and IgG antibodies. The CD45-null mice showed little to no antibody production, as expected (Fig. 9) . The titers of anti-DNP IgM and IgG in the sera from the transgenic mice were comparable to those in the C57BL/6 mice ( Fig. 9) with the peak response occurring 14 days post-immunization for both. 
Discussion
The data presented demonstrate that the LFA-driven CD45.1 minigene in a CD45-null background restores normal splicing characteristics in the hematopoietic cells that express CD45. Importantly, the developmental characteristics of T cells and the functional properties of both T and B cells are also restored. Multiple lines of evidence demonstrate that the LFA-1 controlled CD45.1 transgene is expressed in a pattern characteristic of the endogenous CD45 gene. Flow cytometry data indicate that in transgenic mice hemizygous for CD45.2, all cells positive for CD45.1 were also positive for CD45.2, strongly suggesting that the transgene is expressed in the same cells that express the endogenous gene. Furthermore the major hematopoietic lineages, lymphoid and myeloid, express the CD45.1 transgene. Both RT/PCR and flow cytometry results confirm that alternative splicing of transcripts from the CD45.1 transgene are accurately produced in vivo since the correct cell-type specific isoform expression patterns are generated. Also, naïve and memory CD4 + T cells exhibit the expected CD45RB isoform expression characteristics.
Comparison of endogenous LFA-1 and CD45.2 expression with that of the LFA-1 controlled CD45.1 transgene showed that the transgenic B cell population has characteristics closely resembling the wild type cells, whereas the transgenic T cell lineages express less CD45 compared to wild type. The reason is not known but may be due to the particular properties of the transgene itself, such as the expression characteristics of the LFA-1 promoter. Another possibility is that the integration site has an effect on transgene expression in T cells.
The most important issue, however, is whether the presence of the CD45.1 transgene can overcome the developmental and functional defects resulting from the CD45-null mutation. The presence of the CD45.1 transgene fully restores the number of CD4 + and CD8 + single positive T cells in the thymus and as a result wild type numbers of mature T cells are present in the spleen. Proliferation assays in response to antigen demonstrated that these T cells regained normal signal transduction characteristics through the antigen receptor complex. Therefore, these data confirm that the presence of the CD45.1 minigene restores both T cell development and function.
With respect to B cell function in the transgenic mice, the proliferative response to activation by anti-IgM is restored and suggests that these mice are capable of a humoral immune response to antigen. To test this parameter, the serum anti-DNP IgM and IgG levels of DNP -K LH immunized mice were assayed by ELISA and were found to be similar in both the transgenic and C57BL/6 mice. Thus, the presence of the CD45.1 transgene restores the ability to produce a significant antibody response in vivo.
Since the SCID phenotype exhibited by the CD45-null mice is overcome as a result of the expression of the CD45.1 minigene, a new opportunity can now be considered for treating the CD45-null form of human SCID. A similar human CD45 minigene together with a gene transfer vehicle that can efficiently transfer the 20 kb construct into human hematopoietic cells offers the potential for gene therapy for this otherwise life-threatening genetic disease.
